PLx Pharma Inc

PLx Pharma — Investor Presentation (January 2020)

23 slides from PLx Pharma's investor presentation, Jan 13, 2020

  1. Slide 1: Corporate Presentation

    Corporate Presentation Nasdaq: PLXP Confidential

  2. Slide 2: Forward-Looking Statements

    Confidential 2 Forward - Looking Statements This presentation includes or incorporates by reference statements that constitute forward - looking statements within the meaning of Section 27 A of the Securities Act of 1933 , as amended, and Section 21 E of the Securities Exchange Act of 1934 , as amen

  3. Slide 3: Our Mission

    Confidential 3 Our Mission PLx Pharma is focused on improving the performance of established therapeutic agents with the proprietary PLxGuard ™ targeted drug delivery platform . We are driven to transform the standard of care for millions of patients.

  4. Slide 4: PLx Pharma Investment Highlights

    Confidential 4 PLx Pharma Investment Highlights: Innovative Drug Delivery Platform Overcomes limitations of enteric - coated aspirin with better absorption and safety Large OTC opportunity launching late 2020 , with $10 billion market opportunity A better, liquid aspirin for over 40 million patients

  5. Slide 5: Advancing the Standard of Care Coming Soon

    Confidential 5 Advancing the Standard of Care Coming Soon

  6. Slide 6: Current Aspirin Therapy Landscape

    Confidential 6 Current Aspirin Therapy Landscape Primary Prevention – People without vascular disease ● Daily aspirin for these low risk individuals not routinely recommended ● Doctors can recommend on a case by case basis (i.e. patients with diabetes or low risk of bleeding) Secondary Prevention –

  7. Slide 7: Delayed Release Coated Aspirin: Mechanism of Action & Clinical Implications

    Confidential 7 Delayed Release Coated Aspirin: Mechanism of Action & Clinical Implications Reflux of Aspirin 3 Ulcer: Partially - dissolved coated aspirin in an ulcer crater Stomach P asses largely i ntact through the acidic s tomach environment Duodenum Gradually disintegrates as pH rises Limited P

  8. Slide 8: Targeted Release Liquid Aspirin: Mechanism of Action & Clinical Implications

    Targeted Release Liquid Aspirin: Mechanism of Action & Clinical Implications Stomach Capsule rapidly dissolves and releases the lipid - aspirin complex 1 Duodenum (a) Rising pH dissociates complex (b) Aspirin is free f or absorption 2 Enhanced Protection Reflux back to the low pH of the stomach lead

  9. Slide 9: Comparative Efficacy of Aspirin Formulations

    Editor - in - Chief Top Picks 2017 Confidential 9 Comparative Efficacy of Aspirin Formulations Time to complete antiplatelet response: Plain Aspirin 16.7h VAZALORE 12.5h EC aspirin 48.2h BACKGROUND: The root cause of aspirin resistance remains unknown OBJECTIVES: Determine whether formulation depend

  10. Slide 10: PK/PD Comparison of ASA, ECASA & VAZALORE

    Confidential 10 PK/PD Comparison of ASA, ECASA & VAZALORE: Implications for Aspirin Efficacy Inhibition of serum TxB2 (%) Hours past dose Plasma Acetylsalicylic acid (ng/ml) PL2200 = VAZALORE™ Patients with complete antiplatelet response: Plain Aspirin 84% VAZALORE 92% EC aspirin 47% Acetylsalicylic

  11. Slide 11: Endoscopic Assessment of Aspirin Formulations: Implications for Gastric Ulcer Risk

    Confidential 11 Endoscopic Assessment of Aspirin Formulations: Implications for Gastric Ulcer Risk Cryer B, et al. Low - Dose Aspirin - Induced Ulceration is Attenuated by Aspirin - Phosphatidylcholine: A Randomized Clinical Trial. Am J Gastroenterol 2011; 106(2):272 - 7 PL2200 = VAZALORE™ (a) Subje

  12. Slide 12: VAZALORE: Realizing Aspirin's Full Potential

    VAZALORE: Realizing Aspirin’s Full Potential 71% lower risk of ulcers than regular aspirin Confidential Up to 5X higher absorption than coated aspirin 2X better platelet response than coated aspirin 12 VAZALORE delivers fast, reliable and safe aspirin therapy

  13. Slide 13: VAZALORE U.S. Market Opportunity: $10 Billion

    Market Share Factory (millions) Retail (millions) 1% $70 $100 5% $350 $500 Vascular Patients: All patients with Atherosclerotic Cardiovascular Disease ( ASCVD ) defined by having a previous event such as heart attack or stroke or a previous procedure such as cardiac stent, bypass operation, carotid

  14. Slide 14: High Intent to Prescribe VAZALORE

    Confidential 14 High Intent to Prescribe VAZALORE Consumers (2,000 surveyed) were more likely to purchase specific OTC products when prescribed by a physician 1 Weinman Schnee Morais Inc. Cardiologists Neurologists Endocrinologists Diabetologists GPs Number of Physicians: 201 100 100 104 WOULD PRESC

  15. Slide 15: VAZALORE Commercial Strategy

    Confidential 15 VAZALORE Commercial Strategy ● Thought Leaders ● New Standard of Care PROFESSIONAL ● New life to category ● Premium $ TRADE ● Awareness/Education ● Compliance CONSUMER

  16. Slide 16: Key VAZALORE Messages to HCPs

    Confidential 16 Key VAZALORE Messages to HCPs Better safety with lower risk for ulcers VAZALORE will transform the standard of care Innovative liquid aspirin formula Faster, predictable and reliable antiplatelet efficacy

  17. Slide 17: Milestones - 2019

    Confidential 17 Milestones - 2019 325mg Labeling Approved Stability & Dissolution Testing Registration Batches FDA Meeting Development Scale Batches Q1 2019 Q2 2019 Q3 2019 4Q 2019 End of 2019

  18. Slide 18: Path Forward to VAZALORE Launch

    Confidential 18 Path Forward to VAZALORE Launch Launch VAZALORE FDA Review Period CMC sNDA Submission FDA Meeting/ Data Modeling Q1 2020 Q2 2020 End of 2020 Q4 2020 Q3 2020

  19. Slide 19: Pipeline Leverages PLxGuard Platform Technology

    Confidential 19 Pipeline Leverages PLxGuard Platform Technology In clinical ( * ) and pre - clinical ( ** ) proof - of - concept studies, these product candidates demonstrated improved GI safety vs. the in - market drug Product Candidate Type Size VAZALORE Brand Extensions Chronic Pain & Other Vascu

  20. Slide 20: PLx Management Team

    Michael (Mike) J. Valentino Executive Chairman of the Board 35+ years CEO and senior management with successful OTC and Rx brands (OTC brand, Mucinex®: $2.3 billion exit in 4.5 years) Natasha Giordano President and CEO 25+ years CEO and senior management commercialization experience Rita M. O’Connor

  21. Slide 21: Independent Board of Directors & Advisors

    Director Experience Gary S. Balkema • Former global head of Bayer Healthcare LLC and Worldwide Consumer Care Division • Prior VP and General Manager for American Cyanamid Co.’s Lederle Consumer Health Division Tony Bartsh • Portfolio manager and partner at Park West Asset Management • Former investm

  22. Slide 22: PLx Pharma Investment Highlights

    Confidential 22 PLx Pharma Investment Highlights: Innovative Drug Delivery Platform Overcomes limitations of enteric - coated aspirin with better absorption and safety Large OTC opportunity launching late 2020 , with $10 billion market opportunity A better, liquid aspirin for over 40 million patient

  23. Slide 23: Thank You!

    Thank You! Confidential 23

PLx Pharma — Investor Presentation (January 2020) on 6ix